163 related articles for article (PubMed ID: 38216630)
1. Chemotherapy is of prognostic significance to metaplastic breast cancer.
Zhang M; Yuan J; Wang M; Zhang M; Chen H
Sci Rep; 2024 Jan; 14(1):1210. PubMed ID: 38216630
[TBL] [Abstract][Full Text] [Related]
2. Prognosis in different subtypes of metaplastic breast cancer: a population-based analysis.
He X; Ji J; Dong R; Liu H; Dai X; Wang C; Esteva FJ; Yeung SJ
Breast Cancer Res Treat; 2019 Jan; 173(2):329-341. PubMed ID: 30341462
[TBL] [Abstract][Full Text] [Related]
3. [Effect of postmastectomy radiotherapy on survival outcomes of patients with metaplastic breast cancer].
Cai W; Zhuang Y; Chen J; Wang H
Nan Fang Yi Ke Da Xue Xue Bao; 2021 Nov; 41(11):1733-1740. PubMed ID: 34916202
[TBL] [Abstract][Full Text] [Related]
4. The mixed subtype has a worse prognosis than other histological subtypes: a retrospective analysis of 217 patients with metaplastic breast cancer.
Hu J; Lang R; Zhao W; Jia Y; Tong Z; Shi Y
Breast Cancer Res Treat; 2023 Jul; 200(1):23-36. PubMed ID: 37160814
[TBL] [Abstract][Full Text] [Related]
5. Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer.
Basho RK; Yam C; Gilcrease M; Murthy RK; Helgason T; Karp DD; Meric-Bernstam F; Hess KR; Valero V; Albarracin C; Litton JK; Chavez-MacGregor M; Hong D; Kurzrock R; Hortobagyi GN; Janku F; Moulder SL
Oncologist; 2018 Nov; 23(11):1300-1309. PubMed ID: 30139837
[TBL] [Abstract][Full Text] [Related]
6. Compartmental Syndecan-1 (CD138) expression as a novel prognostic marker in triple-negative metaplastic breast cancer.
Ismail Y; Zakaria AS; Allam R; Götte M; Ibrahim SA; Hassan H
Pathol Res Pract; 2024 Jan; 253():154994. PubMed ID: 38071886
[TBL] [Abstract][Full Text] [Related]
7. Clinical Characteristics and Prognosis of Metaplastic Breast Cancer Compared with Invasive Ductal Carcinoma: A Propensity-Matched Analysis.
Lee JH; Ryu JM; Lee SK; Chae BJ; Lee JE; Kim SW; Nam SJ; Yu J
Cancers (Basel); 2023 Mar; 15(5):. PubMed ID: 36900347
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of Metaplastic Breast Cancer Versus Triple-Negative Breast Cancer: A Propensity Score Matching Analysis.
Tan Y; Yang B; Chen Y; Yan X
World J Surg; 2023 Dec; 47(12):3192-3202. PubMed ID: 37709983
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of a beneficial effect of adjuvant chemotherapy in patients with stage I triple-negative breast cancer: a population-based study using the SEER 18 database.
Du ZL; Wang Y; Wang DY; Zhang L; Bian ZM; Deng Y; Xu CS; Lin DC; Xie L; Jia Y; Gao JD; Zhang BL
Breast Cancer Res Treat; 2020 Sep; 183(2):429-438. PubMed ID: 32647940
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant chemotherapy in pT1ab node-negative triple-negative breast carcinomas: Results of a national multi-institutional retrospective study.
de Nonneville A; Gonçalves A; Zemmour C; Cohen M; Classe JM; Reyal F; Colombo PE; Jouve E; Giard S; Barranger E; Sabatier R; Bertucci F; Boher JM; Houvenaeghel G
Eur J Cancer; 2017 Oct; 84():34-43. PubMed ID: 28780480
[TBL] [Abstract][Full Text] [Related]
11. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes with neoadjuvant versus adjuvant chemotherapy for triple negative breast cancer: A report from the National Cancer Database.
Bagegni NA; Tao Y; Ademuyiwa FO
PLoS One; 2019; 14(9):e0222358. PubMed ID: 31536530
[TBL] [Abstract][Full Text] [Related]
13. Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy.
Bonsang-Kitzis H; Chaltier L; Belin L; Savignoni A; Rouzier R; Sablin MP; Lerebours F; Bidard FC; Cottu P; Sastre-Garau X; Laé M; Pierga JY; Reyal F
PLoS One; 2015; 10(12):e0144359. PubMed ID: 26684197
[TBL] [Abstract][Full Text] [Related]
14. Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study.
Chen Y; Chen K; Xiao X; Nie Y; Qu S; Gong C; Su F; Song E
BMC Cancer; 2016 May; 16():320. PubMed ID: 27198767
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy significantly improves long-term survival of small lesion node negative metaplastic breast carcinoma in T1c population rather than T1a and T1b.
Chen Q; Zhou Q; He H; He Y; Yuan Y; Zou Q; Yi W
Sci Rep; 2022 Jan; 12(1):871. PubMed ID: 35042902
[TBL] [Abstract][Full Text] [Related]
16. Similar outcomes between adenoid cystic carcinoma of the breast and invasive ductal carcinoma: a population-based study from the SEER 18 database.
Chen QX; Li JJ; Wang XX; Lin PY; Zhang J; Song CG; Shao ZM
Oncotarget; 2017 Jan; 8(4):6206-6215. PubMed ID: 28008158
[TBL] [Abstract][Full Text] [Related]
17. Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer.
Yam C; Abuhadra N; Sun R; Adrada BE; Ding QQ; White JB; Ravenberg EE; Clayborn AR; Valero V; Tripathy D; Damodaran S; Arun BK; Litton JK; Ueno NT; Murthy RK; Lim B; Baez L; Li X; Buzdar AU; Hortobagyi GN; Thompson AM; Mittendorf EA; Rauch GM; Candelaria RP; Huo L; Moulder SL; Chang JT
Clin Cancer Res; 2022 Jul; 28(13):2878-2889. PubMed ID: 35507014
[TBL] [Abstract][Full Text] [Related]
18. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
[TBL] [Abstract][Full Text] [Related]
19. The differences in the histological types of breast cancer and the response to neoadjuvant chemotherapy: the relationship between the outcome and the clinicopathological characteristics.
Nagao T; Kinoshita T; Hojo T; Tsuda H; Tamura K; Fujiwara Y
Breast; 2012 Jun; 21(3):289-95. PubMed ID: 22277312
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant Chemotherapy for Metaplastic Breast Cancer: Response Rates, Management, and Outcomes.
Haque W; Verma V; Schwartz MR; Lim B; Mangalampalli N; Butler EB; Teh BS
Clin Breast Cancer; 2022 Jul; 22(5):e691-e699. PubMed ID: 35193807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
